Investigation of a screening programme and the possible identification of biomarkers for early disseminated histiocytic sarcoma in Bernese Mountain dogs

Veterinary and Comparative Oncology

Volumn 10, Issue 2, 2012, Pages 124-134

  Nielsen, L N ^a   McEvoy, F ^a   Jessen, L R ^a   Kristensen, A T ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Ferritin; Haemostasis; Inflammation; Neoplasia

Indexed keywords

TUMOR MARKER;

ANIMAL; ANIMAL DISEASE; ARTICLE; BLOOD; DOG; DOG DISEASE; HISTIOCYTIC SARCOMA; MALE; MASS SCREENING; PATHOLOGY;

ANIMALS; DOG DISEASES; DOGS; HISTIOCYTIC SARCOMA; MALE; MASS SCREENING; TUMOR MARKERS, BIOLOGICAL;

CANIS FAMILIARIS;

EID: 84860345333     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2011.00285.x     Document Type: Article

References (58)

1. Affolter VK and Moore PF. Localized and disseminated histiocytic sarcoma of dendritic cell origin in dogs. Veterinary Pathology 2002; 39: 74-83.
2. Abadie J, Hedan B, Cadieu E, De Brito C, Devauchelle P, Bourgain C, Parker HG, Vaysse A, Margaritte-Jeannin P, Galibert F, Ostrander EA and Andre C. Epidemiology, pathology, and genetics of histiocytic sarcoma in the Bernese mountain dog breed. Journal of Heredity 2009; 100(Suppl. 1): S19-S27.
3. Uehlinger P, Glaus T, Hauser B and Reusch C. Differential diagnosis of hypercalcemia-a retrospective study of 46 dogs. Schweiz Arch Tierheilkd 1998; 140: 188-197.
4. Skorupski KA, Clifford CA, Paoloni MC, Lara-Garcia A, Barber L, Kent MS, LeBlanc AK, Sabhlok A, Mauldin EA, Shofer FS, Couto CG and Sorenmo KU. CCNU for the treatment of dogs with histiocytic sarcoma. Journal of Veterinary Internal Medicine 2007; 21: 121-126.
5. Martin KJ, Fournier MV, Reddy GP and Pardee AB. A need for basic research on fluid-based early detection biomarkers. Cancer Research 2010; 70: 5203-5206.
6. Ronco G, van Ballegooijen M, Becker N, Chil A, Fender M, Giubilato P, Kurtinaitis J, Lancucki L, Lynge E, Morais A, O'Reilly M, Sparen P, Suteu O, Rebolj M, Veerus P, Zakelj MP and Anttila A. Process performance of cervical screening programmes in Europe. European Journal of Cancer 2009; 45: 2659-2670.
7. Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK and Humphrey L. Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Annals Internal Medicine 2009; 151: 727-37, W237-W242.
8. Cheng TI, Wong JM, Hong CF, Cheng SH, Cheng TJ, Shieh MJ, Lin YM, Tso CY and Huang AT. Colorectal cancer screening in asymptomatic adults: comparison of colonoscopy, sigmoidoscopy and fecal occult blood tests. Journal of the Formosan Medical Association 2002; 101: 685-690.
9. Strope SA and Andriole GL. Prostate cancer screening: current status and future perspectives. Nature Reviews Urology 2010; 7: 487-493.
10. Pugliese L, Bernardini I, Pacifico E, Viola-Magni M and Albi E. Antiphospholipid antibodies in patients with cancer. International Journal of Immunopathology and Pharmacology 2006; 19: 879-888.
11. Aggarwal P and Kehoe S. Serum tumour markers in gynaecological cancers. Maturitas 2010; 67: 46-53.
12. Duffy MJ, Evoy D and McDermott EW. CA 15-3: uses and limitation as a biomarker for breast cancer. Clinica Chimica Acta 2010; 411: 1869-1874.
13. Korkmaz M, Unal H, Selcuk H and Yilmaz U. Extraordinarily elevated serum levels of CA 19-9 and rapid decrease after succesfull therapy: A case report and review of literature. The Turkish Journal of Gastroenterology 2010; 21: 461-463.
14. Shu H, Kang X, Guo K, Li S, Li M, Sun L, Gan L, Liu Y and Qin X. Diagnostic value of serum haptoglobin protein as hepatocellular carcinoma candidate marker complementary to alpha fetoprotein. Oncology Reports 2010; 24: 1271-1276.
15. Duffy MJ and Crown J. A personalized approach to cancer treatment: how biomarkers can help. Clinical Chemistry 2008; 54: 1770-1779.
16. Bonazzi M, Volta A, Gnudi G, Cozzi MC, Strillacci MG, Polli M, Longeri M, Manfredi S, Bertoni G. Comparison between ultrasound and genetic testing for the early diagnosis of polycystic kidney disease in Persian and Exotic Shorthair cats. Journal of Feline Medicine and Surgery 2009; 11: 430-434.
17. Ginja MM, Silvestre AM, Colaco J, Gonzalo-Orden JM, Melo-Pinto P, Orden MA, Llorens-Pena MP and Ferreira AJ. Hip dysplasia in Estrela mountain dogs: prevalence and genetic trends 1991-2005. Veterinary Journal 2009; 182: 275-282.
18. Borst GH and Counotte GH. Usefulness of measuring serum lysozyme activity in dogs with neoplastic disease. Veterinary Research Communications 1986; 10: 143-148.
19. Stromberg PC, Schumm DE, Webb TE, Ward H and Couto CG. Evaluation of oncofetal protein-related mRNA transport activity as a potential early cancer marker in dogs with malignant neoplasms. American Journal of Veterinary Research 1995; 56: 1559-1563.
20. Wang J, Brunner CJ, Gangopadhyay A, Bird AC and Wolfe LG. Detection of tumor-associated antigens in sera of canine cancer patients by monoclonal antibodies generated against canine mammary carcinoma cells. Veterinary Immunology and Immunopathology 1995; 48: 193-207.
21. Nielsen L, Andreasen SN, Andersen SD and Kristensen AT. Malignant histiocytosis and other causes of death in Bernese mountain dogs in Denmark. The Veterinary Record 2010; 166: 199-202.
22. Bowbrick VA, Mikhailidis DP and Stansby G. The use of citrated whole blood in thromboelastography. Anesthesia and Analgesia 2000; 90: 1086-1088.
23. Wiinberg B, Jensen AL, Rojkjaer R, Johansson P, Kjelgaard-Hansen M and Kristensen AT. Validation of human recombinant tissue factor-activated thromboelastography on citrated whole blood from clinically healthy dogs. Veterinary Clinical Pathology 2005; 34: 389-393.
24. Kjelgaard-Hansen M and Jensen AL. Is the inherent imprecision of manual leukocyte differential counts acceptable for quantitative purposes? Veterinary Clinical Pathology 2006; 35: 268-270.
25. Brun-Hansen HC, Kampen AH and Lund A. Hematologic values in calves during the first 6 months of life. Veterinary Clinical Pathology 2006; 35: 182-187.
26. Clark P, Mogg TD, Tvedten HW and Korcal D. Artifactual changes in equine blood following storage, detected using the Advia 120 hematology analyzer. Veterinary Clinical Pathology 2002; 31: 90-94.
27. Furlanello T, Tasca S, Caldin M, Carli E, Patron C, Tranquillo M, Lubas G and Solano-Gallego L. Artifactual changes in canine blood following storage, detected using the ADVIA 120 hematology analyzer. Veterinary Clinical Pathology 2006; 35: 42-46.
28. Moritz A, Fickenscher Y, Meyer K, Failing K and Weiss DJ. Canine and feline hematology reference values for the ADVIA 120 hematology system. Veterinary Clinical Pathology 2004; 33: 32-38.
29. Swain AJ, Fuller J and O'Brien PJ. Validation of the ADVIA 1650 chemistry system for the dog and rat. Veterinary Clinical Pathology 2000; 29: 142.
30. Kjelgaard-Hansen M, Jensen AL and Kristensen AT. Evaluation of a commercially available human C-reactive protein (CRP) turbidometric immunoassay for determination of canine serum CRP concentration. Veterinary Clinical Pathology 2003; 32: 81-87.
31. Kjelgaard-Hansen M. Letter to Editor, Comments on Measurements of CRP in dogs. Veterinary Clinical Pathology 2010; 39: 402-403.
32. Andrews GA, Smith JE, Gray M, Chavey PS and Weeks BR. An improved ferritin assay for canine sera. Veterinary Clinical Pathology 1992; 21: 57-60.
33. Beatrice L, Nizi F, Callegari D, Paltrinieri S, Zini E, D'Ippolito P and Zatelli A. Comparison of urine protein-to-creatinine ratio in urine samples collected by cystocentesis versus free catch in dogs. Journal of the American Veterinary Medical Association 2010; 236: 1221-1224.
34. Affolter VK and Moore PF. Canine cutaneous and systemic histiocytosis: reactive histiocytosis of dermal dendritic cells. American Journal of Dermatopathology 2000; 22: 40-48.
35. Moore PF and Rosin A. Malignant histiocytosis of Bernese mountain dogs. Veterinary Pathology 1986; 23: 1-10.
36. Cruz-Arambulo R, Wrigley R and Powers B. Sonographic features of histiocytic neoplasms in the canine abdomen. Veterinary Radiology and Ultrasound 2004; 45: 554-558.
37. Ramirez S, Douglass JP and Robertson ID. Ultrasonographic features of canine abdominal malignant histiocytosis. Veterinary Radiology and Ultrasound 2002; 43: 167-170.
38. Nielsen L, Kjelgaard-Hansen M, Jensen AL and Kristensen AT. Breed-specific variation of hematological and biochemical analytes in healthy Bernese Mountain dogs. Veterinary Clinical Pathology 2010; 39: 20-28.
39. Ola SO, Akanji AO and Ayoola EA. The diagnostic utility of serum ferritin. Estimation in patients with primary hepatocellular carcinoma. Tropical and Geographical Medicine 1995; 47: 302-304.
40. Ito H, Takagi Y, Ando Y, Kubo A, Hashimoto S, Tsutsui F and Kurihara S. Serum ferritin levels in patients with cervical cancer. Obstetrics and Gynecology 1980; 55: 358-362.
41. Ohnishi K, Shimizu K, Yamada H and Kunii A. Quantification of ferritin-secreting cells in patients with non-Hodgkin's lymphoma. Acta Haematologica 1985; 73: 145-149.
42. Linkesch W, Luger T and Kokoschka EM. Serum ferritin in patients with malignant melanoma. Acta Medica Austriaca Suppl 1979; 6: 346-349.
43. Iancu TC. Iron and neoplasia: ferritin and hemosiderin in tumor cells. Ultrastructural Pathology 1989; 13: 573-584.
44. Hann HW, Levy HM and Evans AE. Serum ferritin as a guide to therapy in neuroblastoma. Cancer Research 1980; 40: 1411-3.
45. Ji YY, Liu YF, Wang BY and Yang DY. An immunocytochemical study on the distribution of ferritin and other markers in 36 cases of malignant histiocytosis. Cancer 1989; 64: 1281-1289.
46. Esumi N, Ikushima S, Todo S and Imashuku S. Hyperferritinemia in malignant histiocytosis, virus-associated hemophagocytic syndrome and familial erythrophagocytic lymphohistiocytosis. A survey of pediatric cases. Acta Paediatrica Scandinavica 1989; 78: 268-270.
47. Lukina EA, Levina AA and Mokeeva RA and Tokarev Yu N. The diagnostic significance of serum ferritin indices in patients with malignant and reactive histiocytosis. British Journal of Haematology 1993; 83: 326-329.
48. Newlands CE, Houston DM and Vasconcelos DY. Hyperferritinemia associated with malignant histiocytosis in a dog. Journal of American Veterinary Medical Association 1994; 205: 849-851.
49. Friedrichs KR, Thomas C, Plier M, Andrews GA, Chavey PS and Young KM. Evaluation of serum ferritin as a tumor marker for canine histiocytic sarcoma. Journal of Veterinary Internal Medicine 2010; 24: 904-911.
50. Hugnet C, Hugnet-Bruchon C, Dégorce-Rubailes F and Poujade A. Histiocytose maligne associée à une hypercalcémie paranéoplastique. Pratique médicale & chirurgicale de l'animal de compagnie. 2001; 36: 23-27.
51. Nielsen L, Toft N, Eckersall PD, Mellor DJ and Morris JS. Serum C-reactive protein concentration as an indicator of remission status in dogs with multicentric lymphoma. Journal of Veterinary Internal Medicine 2007; 21: 1231-1236.
52. Kristensen AT, Wiinberg B, Jessen LR, Andreasen E and Jensen AL. Evaluation of human recombinant tissue factor-activated thromboelastography in 49 dogs with neoplasia. Journal of Veterinary Internal Medicine 2008; 22: 140-147.
53. Bacchetta J, Juillard L, Cochat P and Droz JP. Paraneoplastic glomerular diseases and malignancies. Critical Reviews in Oncology/Hematology 2009; 70: 39-58.
54. O'Donnell MR, Slichter SJ, Weiden PL and Storb R. Platelet and fibrinogen kinetics in canine tumors. Cancer Research 1981; 41: 1379-1383.
55. Marconato L, Crispino G, Finotello R, Mazzotti S and Zini E. Clinical relevance of serial determinations of lactate dehydrogenase activity used to predict recurrence in dogs with lymphoma. Journal of American Veterinary Medical Association 2010; 236: 969-974.
56. Moore PF, Affolter VK and Vernau W. Canine hemophagocytic histiocytic sarcoma: a proliferative disorder of CD11d+ macrophages. Veterinary Pathology 2006; 43: 632-645.
57. Tryggvadottir L, Gislum M, Bray F, Klint A, Hakulinen T, Storm HH and Engholm G. Trends in the survival of patients diagnosed with breast cancer in the Nordic countries 1964-2003 followed up to the end of 2006. Acta Oncologica 2010; 49: 624-631.
58. Nielsen L, Wiinberg B, Kjelgaard-Hansen M, Jensen AL and Kristensen AT. Prolonged activated prothromboplastin time and breed-specific variation in hemostatic analytes in healthy Adult Bernese Mountain dogs. The Veterinary Journal 2010; doi:10.1016/j.tvjl.2010.09.016.